
Spain’s competition authority, the CNMC, is expected to greenlight BBVA’s planned acquisition of Banco Sabadell as early as next week, according to Reuters, marking a significant step forward in a contentious bid that has drawn attention across the financial sector.
Citing two individuals familiar with the proceedings, Reuters reported that the CNMC’s approval will likely include certain conditions—known as remedies—intended to address potential market concerns. However, one of the sources indicated that these conditions are not anticipated to be particularly burdensome.
The deal, valued at over 12 billion euros ($13.65 billion) when first proposed, represents one of the most high-profile and aggressive banking takeovers in Spain in recent years. BBVA surprised the market in May last year when it launched a hostile bid for its smaller rival, aiming to form a banking giant with more than 1 trillion euros in assets.
Related: Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
According to Reuters, BBVA views the merger as a strategic move to enhance its scale and competitiveness, particularly in a challenging financial landscape shaped by low interest rates. The enlarged entity would seek to strengthen its footing both domestically and across key international markets.
While the CNMC’s decision would mark an important milestone, the deal must still navigate additional regulatory and shareholder scrutiny before completion.
Source: Reuters
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas